BTIG raised the firm’s price target on Sophia Genetics to $8 from $7 and keeps a Buy rating on the shares. The company’s headline Q4 results “didn’t dazzle”, though its new customer adds and early progress in liquid biopsy were the key highlights of the quarter, the analyst tells investors in a research note. Sophia Genetics also established a “conservative or prudent” guide for 2024, driving the post-earnings decline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SOPH:
- Sophia Genetics sees 2024 revenue $78M-$81M, consensus $82.11M
- SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results
- Sophia Genetics reports Q4 EPS (37c) vs. (22c) last year
- Is SOPH a Buy, Before Earnings?
- SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care Conference
